USA Archives

News and Trends 2 Aug 2022

COUR NanoParticle technology halts Type 1 diabetes progression

COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, looking at type 1 diabetes. COUR develops novel immune-modifying nanoparticles (COUR NanoParticles or CNPs) designed to reprogram the immune system in treating autoimmune disorders. The data demonstrated durable tolerance using its novel platform technology in the non-obese diabetic (NOD) model […]

August 2, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 2 Aug 2022

SNIPR Biome announces new patent granted for applications targeting E. coli infections

SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […]

August 2, 2022 - 2 minutesmins - By Liza Laws

In Depth 1 Aug 2022

The biggest US biotech investments in July 2022

The asthma specialist Areteia Therapeutics took the U.S.’ top private biotech investment crown in July 2022, with runners-up including liquid biopsy firm Delfi Diagnostics and the metabolic disease drug developer Carmot Therapeutics. The U.S.’ top private biotech investments in July 2022 didn’t reach the giddy heights of National Resilience’s $625 million Series D round in […]

August 1, 2022 - 3 minutesmins - By Jonathan Smith

More News! 29 Jul 2022

Cancer patients enrolled on study to predict immunotherapy response

An observational study has started enrolling patients with advanced/metastatic non-small cell lung cancer (NSCLC). Florida-based Nilogen Oncosystems made the announcement today (July 29) that those who are receiving immune checkpoint inhibitors in the standard of care will be registered for the study. Using advanced artificial intelligence and machine learning algorithms to discover biomarker signatures as […]

July 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Jul 2022

VerImmune raises $2.5M to develop virus-inspired particle immunotherapies

VerImmune, Inc., a U.S. biotech company developing new therapeutic modalities that aim to redirect the body’s pre-existing immunity toward cancer, has obtained $2.5 million in seed funding. The round was led by SeedFolio, a seed series venture capital firm. The round also included participation from U.S. and global investment venture firms such as Ulu Ventures, […]

July 29, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment

U.S. company Sarepta Therapeutics, Inc. said it intends to submit a Biologics License Application (BLA) seeking accelerated approval for SRP-9001 (delandistrogene moxeparvovec) to treat ambulant individuals with Duchenne muscular dystrophy. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche. “We are delighted to confirm that based on the feedback we […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jul 2022

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Novasenta Inc., a U.S. startup biotech company focused on the discovery and validation of novel targets to develop cancer therapies, has completed $40 million in Series A financing. The round was led by UPMC Enterprises. The funding will allow Novasenta to advance its pipeline of antibody-based therapeutics and expand its computational platforms for target discovery, […]

July 29, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Jul 2022

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

A drug to target a rare genetic form of a neurological disease that affects the nerve cells, leading to the loss of everyday functions, could be the first of its kind available if approved. The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Massachusetts-based Biogen Inc. for tofersen, an […]

July 28, 2022 - 4 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […]

July 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 28 Jul 2022

Commercial launch of Monkeypox PCR test announced for research

A PCR test to pick up the monkeypox virus is now available outside the US for use in research applications by laboratories. Becton, Dickinson and Company (BD) a global medical technology company and CerTesy Biotec made the announcement today (July 27). The BD MAX System used to leverage the test is a fully integrated, automated […]

July 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 27 Jul 2022

T-cell therapy company AlloVir set to raise $126.6M

AlloVir, Inc., a late clinical-stage allogeneic T-cell immunotherapy company, has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of common stock in a registered direct offering at a purchase price of $4.61 per share. Gross proceeds from the offering will equal approximately $126.6 million. The […]

July 27, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jul 2022

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […]

July 26, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

COUR NanoParticle technology halts Type 1 diabetes progression

SNIPR Biome announces new patent granted for applications targeting E. coli infections

The biggest US biotech investments in July 2022

Cancer patients enrolled on study to predict immunotherapy response

VerImmune raises $2.5M to develop virus-inspired particle immunotherapies

Sarepta looks for quick approval for Duchenne muscular dystrophy gene therapy treatment

Biotech startup Novasenta raises $40M to advance novel cancer therapeutics

Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

Commercial launch of Monkeypox PCR test announced for research

T-cell therapy company AlloVir set to raise $126.6M

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!